Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Scope of Consolidation - Schedule of List of Company Directly or Indirectly Controlled (Details)

v3.22.4
Scope of Consolidation - Schedule of List of Company Directly or Indirectly Controlled (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Nuova Ompi S.r.l. | Direct Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Production of drug containment solutionss and development of integrated solutions for the pharmaceutical industry  
Country of incorporation Italy  
% equity interest 100.00% 100.00%
Spami S.r.l. | Direct Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Engineering  
Description Production plant and machinery  
Country of incorporation Italy  
% equity interest 100.00% 100.00%
Stevanato Group International a.s. | Direct Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Holding  
Description Service/Subholding company  
Country of incorporation Slovakia  
% equity interest 100.00% 100.00%
Medical Glass a.s.    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Country of incorporation Slovakia  
Medical Glass a.s. | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Production of drug containment solutions  
Country of incorporation Slovakia  
% equity interest 99.74% 99.74%
Stevanato Group N.A. S. de RL de CV | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Service company  
Country of incorporation Mexico  
% equity interest 100.00% 100.00%
Ompi N.A. S. de RL de CV | Direct Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Production of drug containment solutions  
Country of incorporation Mexico  
% equity interest 30.76% 30.76%
Ompi N.A. S. de RL de CV | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
% equity interest 69.24% 69.24%
Ompi of America inc. | Direct Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Sale of drug containment solutions and analytical services  
Country of incorporation USA  
% equity interest 83.73% 0.00%
Ompi of America inc. | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
% equity interest 16.27% 100.00%
Ompi do Brasil I. e C. de Em. Far. Ltda | Direct Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Production of drug containment solutions  
Country of incorporation Brazil  
% equity interest 79.00% 79.00%
Ompi do Brasil I. e C. de Em. Far. Ltda | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
% equity interest 21.00% 21.00%
Innoscan A/S | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Engineering  
Description Production plant and machinery  
Country of incorporation Denmark  
% equity interest 0.00% 100.00%
Ompi Pharm. Packing Techn. Co. Ltd | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Production of drug containment solutions  
Country of incorporation China  
% equity interest 100.00% 100.00%
SVM Automatik A/S | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Engineering  
Description Production plant and machinery  
Country of incorporation Denmark  
% equity interest 100.00% 100.00%
Medirio SA | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Research and development  
Country of incorporation Switzerland  
% equity interest 100.00% 100.00%
Balda Medical Gmbh | Direct Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Production of in-vitro diagnostic solutions  
Country of incorporation Germany  
% equity interest 100.00% 100.00%
Balda C. Brewer Inc. | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Production of in-vitro diagnostic solutions  
Country of incorporation USA  
% equity interest 100.00% 100.00%
Balda Precision Inc. | Indirect Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Production metal components  
Country of incorporation USA  
% equity interest 100.00% 100.00%
Ompi of Japan Co., Ltd.    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Country of incorporation Japan  
Ompi of Japan Co., Ltd. | Direct Control    
Disclosure Of Significant Investments In Subsidiaries [Line Items]    
Segment Biopharmaceutical  
Description Sale of drug containment solutions  
Country of incorporation Japan  
% equity interest 51.00% 51.00%